Fig. 3: Resmetirom-mediated changes in markers of liver injury and sex-hormone bindingglobulin. | Nature Medicine

Fig. 3: Resmetirom-mediated changes in markers of liver injury and sex-hormone bindingglobulin.

From: Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Fig. 3

a–d, Mean ALT (a), AST (b) and GGT (c) in the subgroup with baseline ALT levels ≥30 IU l−1 and SHBG (nmol l−1) (d) levels over time. Shown are observed data (100 mg OL n = 83; 100 mg DB n = 157; 80 mg DB n = 169; placebo n = 156). Data are presented as mean ± s.e.m.

Back to article page